The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: A modelling study

European Journal of Preventive Cardiology

Volumn 13, Issue 4, 2006, Pages 523-528

  Marshall, Tom ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

cardiac rehabilitation; heart rate recovery; myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; ENALAPRIL; FELODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOSE RESPONSE; DRUG COST; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MODEL; PREMEDICATION; PRIORITY JOURNAL; PROPHYLAXIS; SENSITIVITY ANALYSIS; UNITED KINGDOM;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; ENGLAND; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MODELS, ECONOMIC; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RETROSPECTIVE STUDIES;

EID: 33746716911     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000230098.63277.61     Document Type: Article

References (21)

1. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al Guidelines for management of hypertension: report of the fourthworking party of the British Hypertension Society, 2004: BHSIV. J Hum Hypertens 2004; 18: 139–185.
2. Department of Health. Health survey for England 1998. http://www.data-archive.ac.uk/ [Accessed 25th February2003].
3. Anderson KM, Odell PM, Silson PWF, Kannel WB. Cardiovascular disease riskprofiles. Am Heart J 1991; 121: 293–298.
4. Anderson KA, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statementfor health professionals. Circulation 1991; 83: 356–362.
5. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from theFramingham study. Stroke 1991; 22: 312–318.
6. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention ofcardiovascular events: a summary of the evidence for the U.S. PreventiveServices Task Force. Ann Intern Med 2002; 136: 161–172.
7. British Medical Association. Royal Pharmaceutical Society of Great Britain. British NationalFormulary 48. September 2004. http://bnf.vhn.net/home/[Accessed 2nd February 2005].
8. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–1689.
9. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment withblood pressure lowering drugs: analysis of 354 randomisedtrials. BMJ 2003; 326: 1427–1432.
10. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al Effect of antihypertensive drug treatment on cardiovascularoutcomes in women and men. A meta-analysis of individual patient data fromrandomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126: 761–767.
11. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al Blood pressure, stroke, and coronary heart disease. Part 1,Prolonged differences in blood pressure: prospective observational studiescorrected for the regression dilution bias. Lancet 1990; 335: 765–774.
12. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberiein KA, et al Blood pressure, stroke, and coronary heart disease. Part 2,short-term reductions in blood pressure: overview of randomised drug trialsin their epidemiological context. Lancet 1990; 335: 827–839.
13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low densitylipoprotein cholesterol, ischaemic heart disease, and stroke: systematicreview and meta-analysis. BMJ 2003; 326: 1423–1426.
14. Netten A, Curtil L. Unit costs of health and social care 2002. Personal Social Services Research Unit. University of Kent. http://www.pssru.ac.uk/uc2002.htm. [Accessed 25th April2003].
15. Compiled on behalf of the Department ofHealth by the Prescription Pricing Authority. Drug TariffJan 2002. London: HMSO; 2002.
16. U.S. Preventive Services Task ForceAspirin for the Primary Prevention of Cardiovascular Events: Recommendations and Rationale. AnnIntern Med 2002; 136: 157–160.
17. Assessment and Management of CardiovascularRisk New Zealand Guidelines Group (NZGG) Date Published: 8-Dec-03http://www.nzgg.org.nz/guidelines/dsp_guideline_popup.cfm?guidelineCatID=32&guidelineID=35[Accessed 11th March 2004].
18. Collaborative Group of the PrimaryPrevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk:a randomised trial in general practice. Lancet 2001; 357: 89–95.
19. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension inactual practice. Can Med Assoc J 1999; 160: 31–37.
20. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderlypatients with and without acute coronary syndromes. JAMA 2002; 288: 462–467.
21. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapyin elderly patients. JAMA 2002; 288: 455–461.